Rallybio Corporation – Material Contracts Watch

from S-4/A 10 pages September 25, 2026 Herb C. Cross [***] Re: Employment Terms Dear Herb, Avenzo Therapeutics, Inc. (The “Company”) Is Pleased to Offer You At-Will Employment in the Position of Chief Financial Officer on the Terms and Conditions Set Forth in This Letter Agreement (The “Agreement”)

from S-4/A 2 pages Avenzo Therapeutics, Inc. September 2, 2026

from S-4/A 2 pages Avenzo Therapeutics, Inc. September 2, 2026

from S-4/A 2 pages Avenzo Therapeutics, Inc. November 20, 2024

from S-4/A 2 pages Avenzo Therapeutics, Inc. October 1, 2024

from S-4/A 9 pages Indemnification Agreement

from 8-K 4 pages Side Letter to Employment Agreement

from S-4/A 18 pages Second Amendment to Office Lease

from S-4 17 pages First Amendment to Office Lease

from S-4 59 pages Office Lease 11/7/2022

from S-4 101 pages Collaboration and License Agreement by and Between Avenzo Therapeutics, Inc. and Duality Biologics (Suzhou) Co., Ltd. Dated as of December 23, 2024

from S-4 3 pages Amendment No.1 to Collaboration, Exclusive Option and License Agreement

from S-4 95 pages Collaboration, Exclusive Option and License Agreement by and Between Avenzo Therapeutics, Inc. and Velavigo (Shanghai) Limited and for Purposes of Sections 5.8 and 5.9 and Articles 18 and 19, Velavigo Bio, Inc. Dated as of November 16, 2024

from S-4 100 pages Collaboration and License Agreement by and Between Avenzo Therapeutics, Inc. and Allorion Therapeutics Inc. Dated as of January 3, 2024

from S-4 13 pages Avenzo Therapeutics, Inc

from S-4 13 pages Avenzo Therapeutics, Inc

from S-4 12 pages Avenzo Therapeutics, Inc

from S-4 19 pages Avenzo Therapeutics, Inc. Common Stock Purchase Agreement

from S-4 38 pages Avenzo Therapeutics, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: August 15, 2022| Approved by the Stockholders: August 15, 2022 Amended by the Board of Directors: August 17, 2022 Amended by the Board of Directors: September 13, 2022 Amended by the Board of Directors: March 6, 2023 Approved by the Stockholders: March 6, 2023 Amended by the Board of Directors: March 11, 2024 Approved by the Stockholders: March 11, 2024 Amended by the Board of Directors: March 21, 2024 Approved by the Stockholders: March 21, 2024 Amended by the Board of Directors: November 4, 2024 Approved by the Stockholders: November 4, 2024 Amended by the Board of Directors: June 6, 2025 Approved by the Stockholders: June 16, 2025 Amended by the Board of Directors: August 21, 2025 Approved by the Stockholders: August 21, 2025 Amended by the Board of Directors: September 17, 2025 Approved by the Stockholders: September 17, 2025 Termination Date: August 14, 2032

from 8-K 3 pages Amendment to Confidential Release and Separation Agreement